Topic Listing for ZymoGenetics

Acceleration Vesting Accounting
Accounting Impact Accounting Reconciliation
Accounting Uncertainty Income Taxes Accrued Liabilities
Accrued Rights Ackground
Acknowledgement Regarding Disclosure Acknowledgment Regarding Compensation
Acquired Awards Acquisition Hepatitis Program Due Change Control
Action Violation Law Adjustment Shares
Adjustments Due Technical Changes Administration Interpretation Plan Administrator
Administration Jsc Adverse Event Reporting
Affiliates Agreement
Agreement Loan Agreements Parties
Alliance Manager Defined 341 Allocation Party Development Tasks Commercialization
Alt Executive Chief Officer Alt Executive President
Alt Executive Svp Evp Alt Executive Svp Evp President
Alternatives Considered Amended Restated Effective 2007
Amended Restated Effective 2009 Amended Restated Strategic Alliance Agreement
Amendment Amendment Manufacturing Services Agreement Relating Rhthrombin
Amendment Suspension Termination Plan Amendments
Amendments Waivers Amendments Writing
Annual Grants Annual Report Zymogenetics Form 10-k 2004 Filed Included
Annual Report Zymogenetics Form 10-k 2005 Filed Included Anticipate Incurring Additional Losses Not Achieve Profitability
Appendix Executive Director Compensation 2008 Appointment
Approved Product Labeling Fda Restrictions Promotional Communications Adversely Arbitration
Assignability Assignment
Assistance Atacicept
Atacicept Formerly Known Taci-ig Attendance Annual Meeting
Attendance Meeting Audits
Authority License Authority License Ownership Zymo Enabling Technology
Authorized Disclosure Authorized Number Shares
Automatic Termination Availability Novel Genomic Data Continues Decrease Negatively Affects
Background Background Statement
Balance Sheets Bankruptcy
Base Pay Base Salaries
Basis Presentation Bayer
Bayer Healthcare Pharmaceuticals Inc Bayer Healthcare Rely Co-promote Recothrom Provide Additional Medical
Bayer License Collaboration Agreement Rthrombin Co-promotion Recothrom Bayer Schering Pharma
Bayer Schering Pharma Agreements Bayer Technology
Because Currently Sales Capabilities Limited Marketing Unable Successfully Because Depend Parties Conduct Certain Laboratory Tests Clinical
Because Depend Parties Conduct Laboratory Tests Clinical Trials Benchmarking
Beneficial Ownership Reporting Compliance Benefit Parties
Binding Agreement Bioinformatics
Bioinformatics-based Discovery Strategy Unproven Genes Proteins Discovered Commercial Biological Hazardous Materials Manner Causes Contamination Injury Violates
Black-scholes Value Bms
Bms Efforts Outside Joint Development Project Bms Sole Primary Roles Commercialization
Board Directors Recommends Vote Favor Proposal Outlined Proxy Board Directors Recommends Vote Favor Proposals Outlined Proxy
Books Records Bristol-myers Squibb
Bristol-myers Squibb Agreement Bristol-myers Squibb Co-development Co-promotion Agreement Peg-ifn-
Bristol-myers Squibb Forward-looking Statements Bruce Carter
Building Located Business Condition
Business Highlights Business Judgments Bms Tie-breaking Vote
Business Overview Business Strategy
Cap Research Costs Cash Equivalents
Cash Flows Financing Activities Cash Flows Investing Activities
Cash Flows Operating Activities Cause
Certain Definitions Certain Parties Hold Patents Relating Thrombin
Certain Relationships Related Transactions Certain Relationships Related Transactions Director Independence
Certain Shareholders Significant Control Management Affairs They Exercise Certain Transactions
Certificates Shares Transfer Certifications
Chairman Board Change Control
Change Control Period Change-in-control Provisions Amended Restated 2000 Stock Incentive Plan
Changes Internal Control Over Financial Reporting Choice Law
Clients Obligations Clinical Regulatory Affairs
Clinical Trial Data Clinical Trial Disclosures
Clinical Trials Fail Demonstrate Safety Effectiveness Product Candidates Co-promotion Right
Co-promotion Team Plan Code 162 Provisions
Code 409a Code Definitions
Codes Guidelines Policies Published Pharmaceuticals Research Manufacturers America Collaboration Election Because Serono Not Wish Perform Research
Collaboration Election Because Zgen Not Wish Perform Research Collaboration Election Procedure
Collaborations Leverage Capabilities Not Successful Collaborations Licenses
Collaborative Research Following Collaboration Election Combination Studies Bms Molecules
Combined Conversion Election Co-fund Only Commercial Manufacture
Commercial Product Commercial Sale Means Country Affiliate Sublicensee Licensed
Commercialization Commercialization Diligence Adjustment Territory
Commercialization Leaders Appointment Role Responsibilities Commercialization Row
Commercialization Usa Common Stock
Common Stock Par Value Compensation Committee Interlocks Insider Participation
Compensation Committee Report Compensation Directors
Competing Product Due Change Control Competing Program Product Exclusivity Term
Competition Competitive Benchmarks
Competitors Substantially Greater Capabilities Resources Able Develop Commercialize Complaints Adverse Events Reporting
Compliance Compliance Applicable Laws
Compliance Laws Compliance Laws Regulations
Composition Tribunal Comprehensive Income Loss
Comprehensive Loss Concentration Risks
Conditions Disbursements Conduct Negotiations
Conference Call Webcast Information Confidentiality
Confidentiality Materials Publicity Confidentiality Non-use
Confidentiality Research Materials Publicity Conflict
Consent Assignment Consent Independent Registered Public Accounting Firm
Consent Participant Contact
Contingencies Continuing Directors Terms Ending 2006
Continuing Directors Terms Ending 2007 Continuing Directors Terms Ending 2008
Continuing Directors Terms Ending 2009 Continuing Directors Terms Ending 2010
Continuing Directors Terms Ending 2011 Continuing Exchange Technology
Continuing Performance Contracts Loans Checks Deposits
Contractual Obligations Control Means Ability Grant Licenses Sublicenses Without
Controlling Law Controls Procedures
Conversion Fees Component Costs Coordination Committee
Copyright Registrations Core Patents
Core Patents Means Patent Rights Within Zymo Containing Corporate Existence Power Authority
Corporate Restructuring Cost Product Sales
Cost Sharing Joint Development Costs Cost Sharing Ratio
Costs Counterparts
Countries Within Asia Pacific Region Countries Within Canada Latin America Region
Countries Within Europe Covenants
Creation Direct Financial Obligation Off-balance Sheet Arrangement Credit Generic Products
Credit Party Commercial Fees Paid Bms Critical Accounting Estimates
Cumulative Credits Cumulative Remedies
Cumulative Royalties Aggregation Allocation Net Sales Determining Royalty Currently Marketed Products
Data Exclusivity Regulatory Listings David Maccallum Appointed Zymogenetics Board Directors
Debarment Debarment Proceedings
Debt Financing Decide Build Acquire Own Commercial Manufacturing Capacity Process
Decision Making Administrative Matters Decision Making Formalities
Deerfield Funds Defense Enforcement Actions
Defense Party Infringement Claims Deferred Compensation
Deferred Compensation Plan Deferred Compensation Plan Key Employees
Defined Contribution Definitions
Definitions Terminology Delegation Affiliates
Departure Directors Certain Officers Election Appointment Compensatory Departure Directors Principal Officers Election Appointment
Dependent Efforts Bayer Schering Market Promote Recothrom Countries Designation Collaboration Products
Designation Tenants Parking Spaces Designation Usa Vendor
Determining Executive Compensation Development Marketing Agreement
Development Reports Records Diligence Milestones Royalties
Director Compensation Director Compensation Table 2006
Director Compensation Table 2007 Director Compensation Table 2008
Directors Executive Officers Corporate Governance Directors Executive Officers Registrant
Disclaimers Discovery Development Licensed Products
Discovery Research Process Dispute Resolution
Disputes Relating Patents Dissolution Liquidation
Distribution Recothrom Highly Concentrated Among Small Group Wholesale Documents Incorporated Reference
Dollar Limitation Dollars Upfront Payment 1575 Total Potential Milestone Payments
Dose Escalation Means Sequentially Administering Increasing Doses Douglas Williams Michael Dwyer James Johnson Nicole Onetto
Drafting Party Legal Counsel Duties
Ecitals Effect 2001 Stock Incentive Plan
Effect Shareholders Effective Date
Effective Date 2004 Effective Date 2005
Effective Date Conversion Effective Date Election Co-fund Only
Effects Termination Efforts Cooperation
Election Directors Eligibility
Eligible Employees Email Shczgicom
Employees Employment Agreement
Employment Agreements Enforceability Authority Current Conflicts
Enforcement Joint Patent Rights Entire Agreement
Entire Agreement Amendment Entry Material Definitive Agreement
Environmental Health Safety Laws Result Liabilities Expenses Restrictions Eport Independent Registered Public Accounting Firm
Equitable Remedies Equity Compensation Plan Information
Escalation Arbitration Escalation Ceos
Escalation Disputes Coordination Committee Level Escalation Joint Executive Committee
Estimates Evaluation Disclosure Controls Procedures
Evaluation Genes Selection Collaborative Research Evidence Awards
Ex-us Core Patents Exact Name Registrant Specified Charter
Exception Termination Safety Reasons Exceptions
Excess Row Royalty Milestone Revenue Share Exchange Act 1934
Exchange Ratio Exchange Technology
Exclusions Executive Compensation
Executive Management Executive Officers
Exercisability Exercise Options
Exercise Price Exercise Price New Stock Options
Exhibits Expand Business Through Acquisition Companies Businesses In-licensing Product
Expand Business Through Acquisition Companies Businesses In-licensing Products Expect Incur Significant Expenses Applying Patent Protection Prosecuting
Expedited Arbitration Disputes Coordination Committee Level Expenses
Expertise Expiration Evaluation Term
Expiration Research Term Exploratory Biology
Exposed Financial Risks Related Foreign Currency Exchange Rates Exposed Risks Related Foreign Currency Exchange Rates
Extraordinary Increases Costs Components Facility Agreement
Factor Factor License Agreements
Fail Increase Sales Recothrom Recombinant Thrombin Successfully Develop Fail Obtain Generate Capital Need Fund Operations Unable
Failure Attract Retain Key Management Other Personnel Decrease Failure Bla
Failure Delay Commencing Completing Clinical Trials Product Candidates Failure Delay Commencing Completing Nonclinical Studies Clinical Trials
Failure Effectively Manage Recothrom Supply Chain Result Inventory Fair Value Financial Instruments
Fair Value Measurements Fda Approval Recothrom 8482 Launch Highlights
Federal Income Tax Consequences Federal Income Tax Consequences 2001 Plan
Finance Contacts Financial
Financial Expectations Financial Market Risks
Financial Reporting Disclosure Audit Process Financial Results
Financial Statements Financial Statements Exhibits
Floor Plan Premises Force Majeure
Foreign Exchange Conversion Form 10-k
Form 10-q Form Deerfield Warrant
Form Grant Awards Form Payment Currency Conversion
Formation Formation Composition Jec Action
Formation Joint Commercialization Committee Licensed Product Formation Joint Development Committee
Formation Research Team Formation Steering Committee
Former Name Address Changed Since Last Report Forward Looking Statements
Forward-looking Statements Fractional Shares
Fredrik Henell Phd Further Actions
Further Adjustment Awards Further Information
Fusion Protein Patents Future Conflicts
General General Business Risks
General Functions Authority Role General Provisions Relating Enforcement Patents
General Release Claims Compliance Executive General Rule
Global Safety Database Pharmacovigilance Gmp Manufacturing Run Meaning Set Forth
Goal Cooperative Decision-making Good Reason
Governance Responsibility Development Commercialization Governing Law
Governing Law Judicial Resolution Government Regulation
Government Rights Acknowledges Sublicensed Patents Identified Subject Obligations Grant
Grant Licenses Other Rights Grant Options
Grant Stock Awards Grant Sublicenses
Grant Sublicenses Contractors Guarantees
Guidelines Recommendations Other Literature Published Various Organizations Affect Guidelines Recommendations Other Literature Published Various Organizations Including
Guiding Principles Hart-scott-rodino Antitrust Improvements Act
Heading Northbound I-5 Heading Southbound I-5
Heading Westbound 520 Health Care System Reimbursement Policies Other Related Regulations
Healthcare System Reimbursement Policies Other Healthcare-related Regulations Change Healthcare System Reimbursement Policies Other Related Regulations Change
Held Friday 2005 Held Thursday 2006
Held Thursday 2007 Held Wednesday 2008
Held Wednesday 2009 Hepatitis
Highlighted Expanded Commercial Operations Pipeline Advancement Hsr Act Filing Effective Date
Humans Icense Greement Ecombinant Actor
Icense Ollaboration Greement Ig-fusion Protein Technology
Il-17rc Il-20
Il-21 Il-21 Mab
Il-29 Il-31
Il-31 Mab Impairment Long-lived Assets
Implied Rights Obligations Important Safety Information
Incentive Stock Option Limitations Income Tax Benefit
Income Taxes Incremental Costs
Indemnification Indemnification Bayer
Indemnification Insurance Indemnification Zgen
Indemnity Independent Contractors
Independent Registered Public Accounting Firm Index
Individual Rights Industry Risks
Information Committees Board Directors Meetings Information Relating Other Expenses Issuance Distribution
Initial Coordination Relationship Initial Grants
Initial Joint Development Project Collaborative Efforts Initial Licensed Product Sales
Initial Transfer Insurance
Intellectual Properties Licenses Intellectual Property
Intellectual Property Ownership Intellectual Property Ownership Prosecution Enforcement
Intellectual Property Risks Interleukin-21 Il-21
Internal Candidates Internal Control Over Financial Reporting
Internal Product Candidates Internal Revenue Code
Interpretation Provision Introduction
Invention Agreements Obligations Assign Invention Agreements Personnel
Invention Agreements Personnel Contractors Inventory
Inventory Obsolescence Investment Impairment
Investor Media Relations Investor Relations Media
Issuance Shares Issued Patents Not Provide Competitive Advantage Meaningful Protection
James Johnson Jan Öhrström
Jdc Responsibilities Joint Development Costs Paid Parties
Joint Development Costs Usa Commercialization Joint Patents Core
Joint Project Technology Lack Familiarity Recothrom Adversely Affect Market Acceptance
Lack Novel Genomic Data Required Pursue Approaches Discovering Landlord Acknowledgement
Landlord Acknowledgment Landlords Consent Sublease
Late Payment Late Payments
Lease Obligation Lease Obligations
Legal Governance Matters License Collaboration Agreement
License Fees Milestone Payments Upfront License Rights
License Serono License Transfer Agreement Il-21 Protein
License Zgen License Zymo
Licensed Product Means Either Know-how Patent Licensed Product Related Infringement
Licenses Licenses Parties
Licensing Fees Limitation Liability
Limitations Limited Composition Matter Patent Protection Recothrom
Limited Experience Developing Commercializing Products Limited Experience Developing Commercializing Products Not Successful
Limited Experience Developing Commercializing Products Not Successful Recothrom Limited Experience Developing Products
Limited Numbers Potential Manufacturers Other Vendors Rely Supply Liquidity Capital Resources
List Exhibits Long-term Incentives
Long-term Incentives Ltis Long-term Investment
Long-term Investments Loss Per Share
Loss Relief Usa Commercialization Managements Report Internal Control Over Financial Reporting
Mandatorily Redeemable Convertible Preferred Stock Manner Option Exercise
Manufacture Accordance Cgmp Applicable Law Manufacture Supply
Manufacturing Manufacturing Facility Limited Capacity Not Continue Comply Applicable
Manufacturing Services Agreement Relating Rhthrombin Market Registrants Common Equity Related Shareholder Matters Issuer
Marketing Sale Pharmaceutical Products Biologics Subject Extensive Regulation Materials
Materials Permitted Uses Matters Arbitrated
Matters Covered Matters Proceed Court
Matters Referred Ceos Medical Education Team Plan
Medical Inquiries Meetings Communications
Membership Membership Jsc
Memorandum Merck Serono
Merck Serono Agreements Merck Serono Development Marketing Agreement Atacicept
Merck Serono Strategic Alliance Agreement Merck Serono Substantial Rights License Proteins Discover Limit
Milestone Fees Milestone Payment
Milestone Payments Misappropriation
Miscellaneous Multiple Copies
Name Person Filing Proxy Statement Other Registrant Names Trade Trademarks
Natural Man-made Disasters Impair Ability Conduct Business Nature Operations
Near-term Success Highly Dependent Approval Commercialization Rhthrombin Lead Near-term Success Highly Dependent Commercialization Recothrom Recombinant Thrombin
Negative Public Opinion Increased Regulatory Scrutiny Genetic Clinical Negotiation Right
Net Loss Per Share Net Sales Threshold
New Biosurgery Business Unit New Indications
Nicole Onetto Nns Diligence Development
Nominee Class Directors Whose Term Expire 2006 Annual Nominee Class Directors Whose Term Expire 2007 Annual
Nominee Class Directors Whose Term Expire 2008 Annual Nominees Class Directors Whose Term Expire 2008 Annual
Nominees Class Directors Whose Term Expire 2009 Annual Nominees Class Directors Whose Term Expire 2010 Annual
Nominees Class Directors Whose Term Expire 2011 Annual Nominees Class Directors Whose Term Expire 2012 Annual
Non-competition Non-licensed Product Related Infringement
Non-solicitation Nonqualified Deferred Compensation Table 2006
Nonqualified Deferred Compensation Table 2007 Nonqualified Deferred Compensation Table 2008
Not Able Generate Revenue Product Candidates Developed Collaborators Not Cumulative
Not Obtain Substantial Additional Funding Acceptable Terms Able Not Successful Developing Internal Manufacturing Capabilities Complying Applicable
Notice Notice Cure Breach
Notice Invalidity Unenforceability Notice Medical Hypothesis Other Party Novo
Notice Special Meeting Shareholders Notice Termination
Notices Notices Required Provided Subtenant Include Without Limitation Copies
Notification Notification Allegation Invalidity
Novel Hepatitis Compound Novo Nordisk
Novo Nordisk Data Sharing Cross-license Agreement Il-21 Novo Nordisk Option License Agreement
Novo Nordisk Serono Substantial Rights License Proteins Discover Objectives Components
Obligations Confidentiality Parties Obligations Novo
Officers Offices
Omitted Confidential Material Been Separately Filed Securities Exchange Operating Lease Commitments
Operating Leases Operating Results Subject Fluctuations Cause Stock Price Decline
Operational Decisions Option Exercise Price
Option Exercises Last Year-end Values Option Exercises Stock Vested Table 2006
Option Exercises Stock Vested Table 2007 Option Exercises Stock Vested Table 2008
Option Grants Last Option License Agreement
Option Rights Option Term
Optional Mediation Options
Orders Delivery Invoicing Payment Product Deficiencies Organization Good Standing
Original Premises Other
Other Benefits Other Changes
Other Collaborations Other Commitments
Other Events Other Income Expense
Other Licenses Royalty Offset Other Matters
Other Matters Litigation Other Out-licensed Product Candidates
Other Proteins Other Rights
Other Risks Other Terms Conditions New Stock Options
Other Transactions Others Identify Previously Unknown Side Effects Recothrom Business
Others Identify Unknown Side Effects Recothrom Known Become Out-licensed Candidates
Out-licensed Commercial Products Out-licensed Product Candidates
Outlook 2008 Outlook 2009
Outside Auditor Outstanding Equity Awards 2007 Year-end Table
Overview Ownership Patent Rights
Parachute Payments Part Other Information
Participants Other Countries Parties Challenge Validity Enforceability Patents
Parties Infringe Patents Parties Infringe Patents Challenge Validity Enforceability
Parties Rights Independently Evaluate Parties Roles
Party Agreements Party Commercial Fees Paid Zymo
Party Development Tasks Party Intellectual Property Reach Through Royalties
Party Patent Ifn-lambda Party Research Fees
Patent Applications Not Result Issued Patents Competitors Commercialize Patent Contacts
Patent Contacts Gene Patent Costs
Patent Field Relating Therapeutic Protein-based Products Subject Great Patent Infringement
Patent Product Means Final Dosage Form Contains Patent Prosecution
Patent Prosecution Partys Efforts Patent Prosecution Partys Efforts Obligations
Patent Protection Protein-based Therapeutic Products Other Biotechnology Inventions Patent Term Extensions
Patent Trademark Prosecution Enforcement Patents Patent Applications Not Result Meaningful Protection Against
Patents Proprietary Rights Patheon Italia Spa
Payment Payment Exercise Price
Payment Instructions Payment Schedule
Payments Based Audit Results Payments Net Profits Usa
Payout Levels Percentage Base Pay Paid Cash Payout Levels Range Options Grants
Peg-ifn Formerly Known Il-29 Peg-ifn-
Peg-interferon Lambda Peg-interferon Lambda Novel Type Interferon Phase Trials
Performance Affiliates Performance Criteria
Performance Link Permitted Disclosures
Perquisites Pharmacovigilance Agreement Procedures Established Coordination Committee
Plan Plan Administrator
Plan Administrator Certification Authority Plan Collaborations Leverage Capabilities Not Successful
Plan Summary Post-termination Exercises
Potential Payments Termination Change Control Potential Post-termination Payments
Pre-approved Contractors Preclinical Clinical Supplies
Preclinical Other Preclinical Pipeline
Preclinical Research Development Press Releases
Primary Endpoint Means Variable Capable Providing Most Prime Lessors Acknowledgment
Prime Lessors Consent Principal Accountant Fees Services
Procedure Procedures Regarding Transactions Related Persons
Process Building Acquiring Own Commercial Manufacturing Capacity Expensive Product Candidates Clinical Development
Product Candidates Even Approved Fda Foreign Regulatory Agencies Product Development Risks
Product Sales Product Sales Returns Allowances
Products Product Candidates Even Approved Fda Foreign Regulatory Products Product Pipeline
Progress Primarily Research Development Increasingly Involved Commercialization Products Progress Primarily Research Development Involved Commercialization Encounter Difficulties
Project Leaders Appointment Role Responsibilities Promissory Notes
Properties Property Equipment
Proposal Election Directors Proposal Ratification Appointment Pricewaterhousecoopers Llp Independent Auditors Zymogenetics
Protection Licensed Product Trademarks Provision Attorney
Provision Information Provisions Charter Documents Prevent Frustrate Attempts Replace Current
Provisions Washington Law Charter Documents Executive Employment Agreements Publications
Publicity Terms Agreement Purchase Commitments
Purpose Qualitative Quantitative Disclosures Market Risk
Quarterly Accounting Reconciliation Quarterly Financial Results
Quorum Rapidly Expanded Field Force Operations Including Sales Personnel
Rate Protection Core Patent Reasons Option Exchange
Recalls Recent Accounting Pronouncements
Recent Development Recent Developments
Recent Workforce Changes Recitals
Reclassifications Recombinant
Recombinant Factor Record Date Outstanding Shares
Records Records Audit
Records Reporting Payment Audits Recothrom
Recothrom Also Referred Rthrombin Recothrom Not Achieve Market Acceptance Generate Significant Revenues
Recothrom Not Been Approved Sale Outside United States Recothrom Product Candidates Even Approved Fda Foreign Regulatory
Recothrom Thrombin Topical Recombinant Recourse Dispute Resolution Procedure
Registrants Telephone Number Including Area Code Registration Rights Agreement
Regulatory Data Regulatory Filings
Regulatory Inspection Right Regulatory Meetings Communications
Regulatory Milestones Regulatory Submissions
Related Party Transactions Relating Type-3 Interferon Family
Relationship Rely Expect Continue Obtaining Maintaining Third-party Relationships Commercialize
Rely Parties Supply Recothrom Other Product Candidates Therefore Remainder Page Blank Signatures Next Pages
Remainder Page Intentionally Left Blank Remedies Indemnities
Report Audit Committee Report Compensation Committee Executive
Report Independent Registered Public Accounting Firm Reporting
Reporting Milestone Events Payment Payments Reporting Payment
Reports Sales Usa Representations Warranties
Representations Warranties Bms Representations Warranties Covenants
Representations Warranties Covenants Serono Representations Warranties Covenants Zgen
Representations Warranties Disclaimers Representations Warranties Zymo
Required Defend Lawsuits Pay Damages Connection Alleged Actual Research Development
Research Development Costs Research Development Programs Fail Result Additional Product Candidates
Research Leaders Appointment Role Responsibilities Research Plan Budget
Reservation Resolution Ceos
Resolution Senior Executives Resolution Zgens Ceo Bayers Business Unit Head
Responsibilities Responsibilities Jsc
Responsibilities Reserved Zgen Responsibility Aware Date Option Terminates
Restricted Stock Units Restructuring Place Additional Strain Resources Adversely Affected Morale
Result Progression Primarily Research Development Involved Commercialization Products Return Materials
Reuse Shares Revenue Recognition
Revenues Review Board
Revocability Proxies Rhthrombin
Rights Assignment Delegation Rights Background Intellectual Property
Rights Bankruptcy Rights Reference
Rights Shareholder Rigorous Government Regulations Relating Development Marketing Approval Promotion
Risk Securities Class Action Litigation Due Expected Stock Risks Related Industry
Risks Related Ownership Stock Role Responsibilities
Roles Responsibilities Romotion Greement
Royalties Royalties Conversion
Royalties Follow Products Royalty Agreement
Royalty Payments Royalty Protection Other Patents Without Applicable Patent Rights
Royalty Revenue Salary
Sale Inventory Sale Land
Sales Bonus Sarbanes-oxley Act 2002
Savings Schedule
Scope Collaboration Seal
Securities Exchange Act 1934 Securities Exchange Filings
Securities Registered Pursuant Act Security Ownership Beneficial Owners Management Related Shareholder Matters
Security Ownership Certain Beneficial Owners Management Related Shareholder Segments
Senior Vice President General Counsel Secretary Separation Agreement Release
Serono Serono Agreements
Serono Development Marketing Agreement Taci-ig Serono Strategic Alliance Agreement
Seronos Right Opt Out Collaborative Research Settlement Awards
Severability Shareholder Communications Board Directors
Shareholder Proposals 2006 Annual Meeting Shareholder Proposals 2007 Annual Meeting
Shareholder Proposals 2008 Annual Meeting Shareholder Proposals 2009 Annual Meeting
Shareholder Proposals 2010 Annual Meeting Shareholders Equity
Sharing Awards Shifted Discovery Efforts Therapeutic Antibodies Limited Experience Face
Shifted Much Discovery Efforts Therapeutic Antibodies Limited Experience Short-term Incentives Stis
Short-term Investments Short-term Long-term Investments
Signature Signature Fee Meaning Set Forth
Signature Page Follows Signatures
Signatures Next Page Solicitation Proxies
Standard Benefits Stis Ltis
Stock Awards Stock Compensation
Stock Incentive Plan Stock Incentive Plans
Stock Options Stock Options Exercisable
Stock Ownership Guidelines Stock Price Performance Graph
Stock Price Volatile Stock Price Volatile Subject Factors Beyond Control
Stock-based Compensation Strategic Alliance Agreement
Strict Construction Structured Payments
Subject Patent Infringement Claims Result Substantial Costs Liability Subject Product Liability Claims Limited Insurance Not Adequately
Sublandlords Acknowledgment Sublease Agreement
Sublessees Acknowledgment Sublessors Acknowledgment
Sublicense Contractors Sublicensing
Submission Matters Vote Security Holders Subsequent Event
Subsequent Events Subtenants Acknowledgment
Success Depend Collaborative Partners Ability Effectively Develop Market Summary Compensation Table
Summary Compensation Table 2007 Supply Rfxiii
Survival Surviving Provisions
Table Contents Taci-ig
Tax Accounting Taxation Incentive Stock Options
Technological Risks Technology Transfer Zgen Services Rfxiii Supply
Tenant Acknowledgment Tender Defense
Term Term New Stock Options
Term Options Term Plan
Term Termination Termination
Termination Bms Convenience Termination Cause Other Good Reason
Termination Convenience Termination Date
Termination Date Shall Meaning Set Forth Employment Termination Executive
Termination License Termination License Respect Contested Patent Rights
Termination Material Breach Termination Other Cause Good Reason Change Control Period
Termination Other Cause Good Reason Not Change Control Termination Payments
Termination Result Death Total Disability Termination Seronos Bankruptcy
Termination Usa Co-promotion Agreement Termination Zgens Bankruptcy
Terminology Terms Novo Agreement
Territorial Restrictions Timing
Total Compensation Transactions
Transactions Accounts Related Parties Transactions Novo Nordisk
Transactions Related Persons Transactions Serono
Transfer Project Following Termination Transition Plan
Treatment Confidential Information Tribunals Jurisdiction
Trust Fund Unable Commercialize Antibody Products
Unable Generate Revenue Product Candidates Developed Collaborators Licensees Unable Protect Unpatented Proprietary Technology Information
Unable Satisfy Rigorous Government Regulations Relating Development Commercialization Unable Satisfy Rigorous Government Regulations Relating Development Marketing
Unable Successfully Commercialize Recothrom Face Substantial Competition University Washington
Unregistered Shares Equity Securities Untrue Statement
Usa Co-promotion Agreement Usa Commercialization Costs Paid Parties
Usa Means United States America 1148 Co-promotion Agreement Validity
Venue Rules Venue Rules Applicable Law
Vesting Exercisability Schedule Vesting New Stock Options
Violation Other Agreements Voting
Voting Agreement Regarding Directors Waiver
Waiver Jury Trial Each Parties Hereto Novo Waiver Non-competition
Waiver Restrictions Warrants
Warranty Disclaimer Website Access Sec Reports
Whereas Whereas Desires Obtain Zgen Grant Rights Such Intellectual
Wind Down Activities Withholding
Working Groups Zgen
Zgen Core Genes Zgen Technology
Zgens Right Opt Out Collaborative Research Zymo
Zymo Ex-us Core Patents Zymogenetics
Zymogenetics 2001 Stock Incentive Plan Zymogenetics Announces Changes Senior Management
Zymogenetics Announces Workforce Reduction Restructuring Zymogenetics Bayer Restructure Recothrom Agreements
Zymogenetics Forward Looking Statements Zymogenetics Forward-looking Statements
Zymogenetics Inc Zymogenetics Merck Serono Restructure Partnership
Zymogenetics Reports 2008 Financial Results Zymogenetics Reports 2009 Financial Results
Zymogenetics Reports End 2008 Financial Results Zymogenetics Secures 100 Funding Commitment
Zymogenetics Secures Worldwide Rights Il-21 Zymos Financial Condition
Zymos Option 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki